{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:17:06Z","timestamp":1782947826360,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejpb.2023.04.023","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T21:03:44Z","timestamp":1683061424000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Population pharmacokinetics and exposure-safety of lipophilic conjugates prodrug DP-VPA in healthy Chinese subjects for dose regime exploring"],"prefix":"10.1016","volume":"188","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peimin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2966-9149","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.04.023_b0005","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/jnr.24861","article-title":"Cardiorespiratory findings in epilepsy: A recent review on outcomes and pathophysiology","volume":"99","author":"Aky\u00fcz","year":"2021","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejpb.2023.04.023_b0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2019.03.019","article-title":"Reflex seizure triggering: Learning about seizure producing systems","volume":"69","author":"Sz\u0171cs","year":"2019","journal-title":"Seizure."},{"key":"10.1016\/j.ejpb.2023.04.023_b0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(15)00398-1","article-title":"The remarkable story of valproic acid","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2710.2007.00831.x","article-title":"Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy","volume":"32","author":"Dutta","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejpb.2023.04.023_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejps.2018.06.033","article-title":"Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors","volume":"122","author":"Xu","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.04.023_b0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","article-title":"Epilepsy in older people","volume":"395","author":"Sen","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.ejpb.2023.04.023_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2021.12.003","article-title":"Combined effects of levetiracetam and sodium valproate on paediatric patients with epilepsy: a systematic review and meta-analysis","volume":"95","author":"Zhu","year":"2022","journal-title":"Seizure."},{"key":"10.1016\/j.ejpb.2023.04.023_b0040","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejpb.2023.04.023_b0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/17425250902911455","article-title":"A review of valproate in psychiatric practice","volume":"5","author":"Haddad","year":"2009","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(88)90052-6","article-title":"Valproate monotherapy in children","volume":"84","author":"Murphy","year":"1988","journal-title":"Am J Med."},{"key":"10.1016\/j.ejpb.2023.04.023_b0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/dta.2579","article-title":"Determination of DP-VPA and its active metabolite, VPA, in human plasma, urine, and feces by UPLC-MS\/MS: A clinical pharmacokinetics and excretion study","volume":"11","author":"Li","year":"2019","journal-title":"Drug Test Anal."},{"key":"10.1016\/j.ejpb.2023.04.023_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.10.025","article-title":"The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration","volume":"126","author":"Dahan","year":"2008","journal-title":"J. Control Release."},{"key":"10.1016\/j.ejpb.2023.04.023_b0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s11095-021-03093-x","article-title":"Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles","volume":"38","author":"Han","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.04.023_b0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/med.21533","article-title":"Lipidic prodrug approach for improved oral drug delivery and therapy","volume":"39","author":"Markovic","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejpb.2023.04.023_b0075","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0000000000000651","article-title":"Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients","volume":"41","author":"Higuchi","year":"2019","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.ejpb.2023.04.023_b0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-018-2600-8","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens","volume":"75","author":"Lin","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcph.1791","article-title":"Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models","volume":"61","author":"Tauzin","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/17512433.2022.2075849","article-title":"Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder","volume":"15","author":"Zang","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(02)00106-7","article-title":"Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)","volume":"51","author":"Bialer","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejpb.2023.04.023_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0920-1211(00)00171-6","article-title":"Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)","volume":"43","author":"Bialer","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejpb.2023.04.023_b0105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bcp.13510","article-title":"A systematic review of population pharmacokinetics of valproic acid","volume":"84","author":"Methaneethorn","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12372","article-title":"Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives","volume":"8","author":"Marshall","year":"2019","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.04.023_b0115","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ejpb.2023.04.023_b0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/clpt.2011.47","article-title":"Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study","volume":"89","author":"Price","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.ejpb.2023.04.023_b0125","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jpba.2017.11.042","article-title":"A rapid and simple HPLC-MS\/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients","volume":"149","author":"Wen","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2023.04.023_b0130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejpb.2023.04.023_b0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","article-title":"Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen","volume":"37","author":"Lin","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejpb.2023.04.023_b0140","first-page":"2043","article-title":"Sodium valproate combined with levetiracetam in pediatric epilepsy and its influence on NSE, IL-6, hs-CRP and electroencephalogram improvement","volume":"20","author":"Liu","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejpb.2023.04.023_b0145","first-page":"520","article-title":"Comparison of the Therapeutic Effects of Sodium Valproate and Levetiracetam on Pediatric Epilepsy and the Effects of Nerve Growth Factor and \u03b3-Aminobutyric Acid","volume":"50","author":"Chen","year":"2021","journal-title":"Iran J. Public Health."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112300111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112300111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:52:54Z","timestamp":1760547174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112300111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":29,"alternative-id":["S093964112300111X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.023","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics and exposure-safety of lipophilic conjugates prodrug DP-VPA in healthy Chinese subjects for dose regime exploring","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}